Financial Performance - Q3 2025 revenue increased by 84.7% year-over-year to $334.2 million, compared to $180.9 million in Q3 2024[47] - Genomics revenue totaled $252.9 million in Q3 2025, a 117.2% increase compared to Q3 2024[51] - Data and Services revenue reached $81.3 million in Q3 2025, a 26.1% increase compared to Q3 2024[51] - Gross profit improved by 98.4% year-over-year, reaching $209.9 million in Q3 2025, compared to $105.8 million in Q3 2024[47] - Adjusted EBITDA was $1.5 million in Q3 2025, a $23.3 million improvement from $(21.8) million in Q3 2024[47] Genomics Business - Oncology testing (Tempus Genomics) revenue was $139.5 million in Q3 2025, a 31.7% year-over-year increase[51] - Hereditary testing (Ambry Genetics) revenue was $102.6 million in Q3 2025, a 32.8% increase on a pro forma basis[51] - Hereditary tests delivered in Q3 2025 were approximately 129,500, with an average reimbursement per test of $790[24] Data and Services - Total Remaining Contract Value (TCV) for Data and Services was over $940 million at the end of 2024[34] - Data Licensing Retention was approximately 140% at the end of 2024[34] Guidance - Full year 2025 revenue guidance increased to approximately $1.265 billion, representing approximately 80% annual growth[60]

Financial Performance - Revenue for Q2 2025 increased by 896% year-over-year to $3146 million from $1660 million in Q2 2024[52, 55] - Genomics revenue reached $2418 million, a 1153% increase compared to Q2 2024[55] - Data and Services revenue totaled $728 million, growing 357% year-over-year, with Insights (data licensing) growing 407%[55] - Gross profit improved by 1583% year-over-year, reaching $1950 million in Q2 2025[52, 55] - Adjusted EBITDA improved by 821%, with a loss of $(56) million in Q2 2025 compared to $(312) million in Q2 2024[52, 55] Genomics Business - Oncology testing (Tempus Genomics) revenue was $1332 million, up 329% year-over-year, with approximately 26% volume growth[55] - Hereditary testing (Ambry Genetics) contributed $973 million of revenue, up 336% year-over-year on a pro forma basis, with approximately 32% volume growth[55] - Average reimbursement per hereditary test was $760 in Q2 2025[24] Data and AI - Total Remaining Contract Value for Data and Services was >$940 million at the end of 2024[39] - Data Licensing Retention was ~140% at the end of 2024[39] - Tempus has >350 petabytes of rich multimodal healthcare data[12, 37]